NextCure

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2015-01-01

Employees: 82

Market Cap: -

Website: http://www.nextcure.com

Introduction: NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Clinical Trials

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Ovarian Cancer
Endometrial Cancer
Breast Cancer
Biliary Tract Cancer
Non-Small Cell Lung Cancer
Advanced or Metastatic Solid Tumors

Interventions: Drug: LNCB74

First Posted Date: 2025-01-14

Last Posted Date: 2025-05-14

Lead Sponsor: NextCure, Inc.

Target Recruit Count: 145

Registration Number: NCT06774963

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Washington University, Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

and more 6 locations

A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

Phase 1

Terminated

Conditions: Relapsed or Refractory Chronic Myelomonocytic Leukemia
Relapsed or Refractory Myelodysplastic Syndrome
Relapsed or Refractory Acute Myeloid Leukemia

Interventions: Drug: NC525

First Posted Date: 2023-03-28

Last Posted Date: 2025-04-24

Lead Sponsor: NextCure, Inc.

Target Recruit Count: 28

Registration Number: NCT05787496

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 8 locations

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors

Phase 1

Active, not recruiting

Conditions: Ovarian Cancer
Colo-rectal Cancer
Advanced or Metastatic Solid Tumors
Lung Cancer
Microsatellite Instability High
Microsatellite Stable
Endometrial Cancer
Cervical Cancer
Esophageal Cancer
Microsatellite Instability Low

Interventions: Drug: NC410
Drug: pembrolizumab

First Posted Date: 2022-10-10

Last Posted Date: 2024-12-16

Lead Sponsor: NextCure, Inc.

Target Recruit Count: 97

Registration Number: NCT05572684

Locations: 🇺🇸
Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸
Rocky Mountain Cancer Centers, Aurora, Colorado, United States
🇺🇸
St. Elizabeth Edgewood Hospital, Edgewood, Kentucky, United States

and more 14 locations

A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Advanced or Metastatic Solid Tumors
Breast Cancer
Ovarian Cancer
Non-small Cell Lung Cancer

Interventions: Drug: NC762

First Posted Date: 2021-05-06

Last Posted Date: 2025-04-22

Lead Sponsor: NextCure, Inc.

Target Recruit Count: 40

Registration Number: NCT04875806

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Inova Schar Cancer Institute, Fairfax, Virginia, United States
🇺🇸
Carolina BioOncology Institute, Huntersville, North Carolina, United States

and more 5 locations

A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC

Phase 1

Withdrawn

Conditions: Advanced or Metastatic Solid Tumors
Non-Small Cell Lung Cancer

Interventions: Drug: NC318
Drug: Nab paclitaxel/Carboplatin
Drug: Docetaxel
Drug: Pemetrexed/Carboplatin

First Posted Date: 2020-06-16

Last Posted Date: 2021-08-18

Lead Sponsor: NextCure, Inc.

Registration Number: NCT04430933

A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Ovarian Cancer
Gastric Cancer
Colo-rectal Cancer
Advanced or Metastatic Solid Tumors

Interventions: Drug: NC410

First Posted Date: 2020-05-29

Last Posted Date: 2024-07-25

Lead Sponsor: NextCure, Inc.

Target Recruit Count: 46

Registration Number: NCT04408599

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
NIH National Cancer Institute (NCI), Bethesda, Maryland, United States

and more 2 locations

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Endometrial Cancer
Melanoma
Lung Cancer
Head and Neck Squamous Cell Carcinoma
Urothelial Carcinoma
Advanced or Metastatic Solid Tumors
Breast Cancer
CRC
Cholangiocarcinoma

Interventions: Drug: NC318

First Posted Date: 2018-09-11

Last Posted Date: 2024-03-08

Lead Sponsor: NextCure, Inc.

Target Recruit Count: 109

Registration Number: NCT03665285

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
NEXT Oncology, San Antonio, Texas, United States

and more 3 locations

Home Terms & Conditions Privacy Policy